| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
BC11-38 targets phosphodiesterase 11 (PDE11), an enzyme that hydrolyzes cyclic AMP (cAMP) and cyclic GMP (cGMP). By inhibiting PDE11, it increases intracellular cAMP and/or cGMP levels, which can modulate various signaling pathways. Its high selectivity for PDE11 over other PDE isoforms makes it a valuable research tool.
|
|---|---|
| ln Vitro |
H295R-initiated cells have higher cAMP levels when exposed to BC11-38 (20 μM; hr) [1].
In vitro, BC11-38 inhibits PDE11 with high potency (IC50 = 0.28 μM) and is highly selective over PDE1-10 (IC50 > 100 μM). It elevates cAMP levels and increases cortisol production in H295R cells. Its activity is measured in enzyme assays and cell-based assays. |
| ln Vivo |
In vivo, BC11-38 is a research compound used to study the role of PDE11 in various physiological processes. Its effects on cAMP signaling and cortisol production have been studied in cell models. It is not a drug candidate.
|
| Enzyme Assay |
The in vitro enzyme inhibition assay for BC11-38 involves measuring its ability to inhibit PDE11 activity. The enzyme is incubated with its substrate (cAMP or cGMP) in the presence of varying concentrations of the compound, and the reduction in product formation is measured. The IC50 is determined.
|
| Cell Assay |
In vitro cellular assays for BC11-38 are performed on H295R human adrenocortical carcinoma cells. Cells are treated with the compound, and the elevation of cAMP levels and increase in cortisol production are measured. Its effects on cell signaling and gene expression are also studied.
|
| Animal Protocol |
In vivo animal experiments for BC11-38 are not extensively documented in the available literature, as it is primarily a research compound. It may be used in animal models to study the role of PDE11 in adrenal function and other physiological processes.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic properties of BC11-38 are not extensively documented in the available literature. As a small molecule with a molecular weight of 304.43 g/mol, it is expected to have reasonable membrane permeability. It is typically stored as a powder and is soluble in DMSO.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for BC11-38 are not readily available in the public domain, as it is primarily a research compound. Its high selectivity for PDE11 suggests a potentially favorable safety profile. As with all research chemicals, standard laboratory safety practices should be followed.
|
| References | |
| Additional Infomation |
BC11-38 is a research compound used to study phosphodiesterase 11 (PDE11). It is also known as BC 11-38. It is not an FDA-approved drug and is exclusively for research purposes. It is a valuable tool for investigating the role of PDE11 in cAMP signaling and adrenocortical function.
|
| Molecular Formula |
C15H16N2OS2
|
|---|---|
| Molecular Weight |
304.430340766907
|
| Exact Mass |
304.07
|
| CAS # |
686770-80-9
|
| PubChem CID |
2052828
|
| Appearance |
White to yellow solid powder
|
| LogP |
3.382
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
20
|
| Complexity |
453
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCSC1=NC2=C(C(=O)N1C3=CC=CC=C3)SCC2
|
| InChi Key |
YHNDCCKFNWDQGW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H16N2OS2/c1-2-9-20-15-16-12-8-10-19-13(12)14(18)17(15)11-6-4-3-5-7-11/h3-7H,2,8-10H2,1H3
|
| Chemical Name |
3-phenyl-2-propylsulfanyl-6,7-dihydrothieno[3,2-d]pyrimidin-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~33.33 mg/mL (~109.48 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.21 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2848 mL | 16.4241 mL | 32.8483 mL | |
| 5 mM | 0.6570 mL | 3.2848 mL | 6.5697 mL | |
| 10 mM | 0.3285 mL | 1.6424 mL | 3.2848 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
